Johnson & Johnson (J&J) has announced an investment of more than $2 billion to build a biologics manufacturing facility in Wilson, North Carolina.  

J&J says the new facility is part of a broader plan to advance more than 70 novel therapy and product expansion filings and launches by the end of the decade. “A strong, global supply chain is crucial, and we purposefully invest to ensure our transformational medicines reliably and efficiently reach patients around the world,” said Dapo Ajayi, Vice President, Innovative Medicine Supply Chain, Johnson & Johnson,” in an October 1, 2024, statement. “We are investing in capacity and new technologies to enhance our industry-leading capabilities and ensure a resilient supply chain for the future.” 

The new facility will expand production of J&J’s biologic medicines in various therapeutic areas, including oncology, immunology, and neuroscience. Construction of the new facility is anticipated to begin in the first half of 2025. When fully operational, the site will employ approximately 420 full-time employees. 

Source: Johnson & Johnson